Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 50 of 78 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/12/24
End: 09/30/28
Due: 09/30/29
Phase: N/A
Priority: Normal
Start: 06/30/10
End: 12/31/14
Due: 12/31/15
Phase: N/A
Priority: Normal
Start: 03/19/18
End: 10/17/19
Due: 10/17/20
Phase: N/A
Priority: Normal
Start: 10/23/23
End: 07/23/25
Due: 07/23/26
Phase: N/A
Priority: Normal
Start: 12/31/14
End: 07/31/17
Due: 07/31/18
Phase: N/A
Priority: Normal
Start: 07/31/25
End: 10/31/26
Due: 10/31/27
Phase: N/A
Priority: Normal
Start: 03/11/24
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 01/01/18
End: 12/31/99
Due: 12/31/00
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Phase: N/A
Priority: Normal
Start: 02/25/25
End: 01/27/27
Due: 01/27/28
Phase: N/A
Priority: Normal
Start: 07/31/23
End: 08/31/25
Due: 08/31/26
Phase: N/A
Priority: Normal
Start: 06/30/24
End: 09/30/25
Due: 09/30/26
Phase: N/A
Priority: Normal
Start: 04/19/19
End: 07/12/19
Due: 07/12/20
Phase: N/A
Priority: Normal
Start: 10/26/23
End: 11/26/25
Due: 11/26/26
Phase: N/A
Priority: Normal
Start: 05/14/18
End: 01/16/19
Due: 01/16/20
Phase: N/A
Priority: Normal
Start: 05/22/23
End: 05/15/24
Due: 05/15/25
Phase: N/A
Priority: Normal
Start: 05/01/18
End: 10/31/18
Due: 10/31/19
Phase: N/A
Priority: Normal
Start: 10/31/13
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 04/30/15
End: 05/31/16
Due: 05/31/17
Phase: N/A
Priority: Normal
Start: 05/31/11
End: 09/30/14
Due: 09/30/15
Phase: N/A
Priority: Normal
Start: 01/01/16
End: 08/01/18
Due: 08/01/19
Phase: N/A
Priority: Normal
Start: 08/17/22
End: 01/31/23
Due: 01/31/24
Phase: N/A
Priority: Normal
Start: 09/22/18
End: 11/24/19
Due: 11/24/20
Phase: N/A
Priority: Normal
Start: 03/01/17
End: 06/01/18
Due: 06/01/19
Phase: N/A
Priority: Normal
Start: 07/16/19
End: 10/10/19
Due: 10/10/20
Phase: N/A
Priority: Normal
Start: 06/01/17
End: 02/24/18
Due: 02/24/19